城堡生物科学公司2025年季度报告

FORM10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period endedSeptember30, 2025OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from_________to_________ Commission File Number:001-38984 CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) 77-0701774 Delaware (I.R.S. Employer Identification No.) (State or other jurisdiction of incorporation ororganization) 505 S. Friendswood Drive,Suite 401,Friendswood,Texas(Address of principal executive offices) 77546(Zip Code) (866)788-9007(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: The Nasdaq Global Market Common Stock, $0.001 par value per share Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrantwas required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☐ Accelerated filer☒Smaller reporting company☐Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the ExchangeAct.☐Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of October27, 2025, there were29,188,659shares of common stock, $0.001 par value per share, issued and outstanding. Table of Contents PagePART I.FINANCIAL INFORMATION1Item 1.Financial Statements1Condensed Consolidated Balance Sheets as ofSeptember30, 2025 (Unaudited) and December31, 20241Unaudited Condensed Consolidated Statements of Operations for the Three andNineMonthsEndedSeptember30, 2025 and 20242Unaudited Condensed Consolidated Statements of Comprehensive(Loss)Incomefor the ThreeandNineMonths EndedSeptember30, 2025 and 20243Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the Three andNineMonths EndedSeptember30, 2025 and 20244Unaudited Condensed Consolidated Statements of Cash Flows for theNineMonths EndedSeptember30, 2025 and 20246Notes to Unaudited Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations27Item 3.Quantitative and Qualitative Disclosures About Market Risk45Item 4.Controls and Procedures46 PART II.OTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSIGNATURES CASTLE BIOSCIENCES, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands, except share and per share data) CASTLE BIOSCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY(UNAUDITED)(in thousands, except share data) CASTLE BIOSCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY(UNAUDITED)(in thousands, except share data) CASTLE BIOSCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(UNAUDITED)(in thousands) CASTLE BIOSCIENCES, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)(UNAUDITED)(in thousands) CASTLE BIOSCIENCES, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(UNAUDITED) 1.Organization and Description of Business Castle Biosciences, Inc. (the “Company,” “we,” “us” or “our”) was incorporated in the state of Delaware on September 12,2007. We are a commercial-stage diagnostics company focused on providing clinicians and their patients withpersonalized, clinically actionable information to inform treatment decisions and improve health outcomes. We are basedin Friendswood, Texas (a suburb of Houston, Texas) and our laboratory operations are conducted at our facilities locatedin Phoenix, Arizona and Pittsburgh, Pennsylvania. 2.Summary of Significant Accounting Policies Basis of Presentation Our unaudited condensed consolidated financial statements include the accounts of